---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-234882"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-05-21T21:12:40+00:00"
generated_at: "2026-05-21T21:16:41.357067+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics schedules June 10 vote on Series B conversion that would trigger change of control

## Summary
- Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.
- Conversion would issue ~24.4M shares, representing >20% of outstanding and result in change of control per Nasdaq rules.
- Pro forma shows reclassification of $321.9M from preferred stock to equity; net loss per share improves from $131.45 to $6.62.
- Conversion contingent on stockholder approval; if approved, occurs three business days after vote.

## SEC filing metadata
- accession: 0001193125-26-234882
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-05-21T21:12:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/0001193125-26-234882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/d162035d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-234882
- JSON: https://secwatch.observer/filing/0001193125-26-234882.json
- Plain text: https://secwatch.observer/filing/0001193125-26-234882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.